The programme, part of routine immunisations, was first rolled out in 42 districts in January 2024, with plans to expand to all 200 districts by the end of next year.

Scott Gordon, Head of Gavi’s Malaria Vaccine Programme, confirmed that the demand for the vaccine is indicative of its success and necessity. The programme has delivered vaccines to 17 endemic countries across Africa, responding to the concerning malaria death toll, which claimed over 13 000 lives in Cameroon alone in 2021.

Initial reports from Cameroon are encouraging. Two of the first recipients, 18-month-old twins Daniel and Daniela, have remained malaria-free since receiving the vaccine. National data reveal a decrease in hospital admissions for malaria-related illnesses among children under five, suggesting a promising early impact of the vaccine. Such positive trends echo earlier pilot implementations of the vaccine in Ghana, Kenya, and Malawi, where a 13% reduction in overall child mortality was recorded.

The selection of Cameroon as the first country for this initiative is rooted in its commitment to combating malaria, a devastating disease predominantly affecting children. As a result, the nation swiftly applied for support through Gavi's malaria programme, allowing for an expedited launch.

Currently, 16 other African nations are implementing the malaria vaccine, with Uganda, Ethiopia, Mali, Guinea, and Burundi among those planning to introduce it within the year. Gavi aims to vaccinate an additional 14 million children by 2025, targeting over 50 million by 2030.

Despite challenges posed by climate change and increasing mosquito populations, Gordon remains optimistic about the vaccine's potential and the overall progress in fighting malaria in Africa. The ongoing efforts paint a hopeful picture for the continent's vulnerable populations, particularly children.

--ChannelAfrica--